-
Featured
New Clues Emerge on Management of Recurrent Nonmuscle Invasive Bladder Cancer After Trimodality Therapy
When nonmuscle invasive bladder cancer develops after trimodality therapy for muscle invasive bladder cancer, salvage radical cystectomy isn't necessarily required, researchers have found.
-
Featured
Modified Paclitaxel Plus Daily Radiation Helps Noncystectomy Candidates
Physicians at Massachusetts General Hospital are in the early stages of testing a novel regimen for patients with muscle-invasive urothelial bladder cancer who are medically unfit for radical cystectomy or platinum-based radiosensitizing chemotherapy.
-
Featured
Orthotopic Neobladder Reconstruction Restores Quality of Life for Female Cystectomy Patients
Orthotopic neobladder reconstruction is becoming the diversion procedure of choice for female cystectomy patients due to recent advances in care for female urology patients.
-
Mass General Offers Novel, Kidney-saving Urothelial Cancer Treatment
Mitomycin chemoablation with a mitomycin gel, a novel treatment offered in the Department of Urology at Massachusetts General Hospital, can avoid the need for surgical removal of the kidney and ureter in patients with upper tract urothelial cancer.
-
Advancing Trimodality Therapy for Bladder Cancer
Researchers explore long-term outcomes and options for bladder cancer recurrence after combination treatment using transurethral resection and chemoradiation.
-
Long-term Safety Profile of Salvage Cystectomy After Trimodality Therapy Seems Acceptable
Salvage cystectomy after trimodality therapy is associated with a higher rate of late complications than primary cystectomy, according to Matthew F. Wszolek, MD, and colleagues. However, the increased risk of late complications does not influence overall survival.
Bladder Contributors
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Prostate Cancer Patients with Posterior Positive Surgical Margins Have Poorer Prognosis
-
Douglas Middleton Dahl, MD
Chief, Division of Urologic Oncology, Director of Robotic Surgery, Associate Professor, Harvard Medical School
Recent Article
Transperineal Prostate Biopsy Feasible in Outpatient Practice
-
Jason A. Efstathiou, MD, DPhil
Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic
Recent Article
Gene Profiling of Bladder Tumors Shows Promise for Identifying Candidates for Trimodality Therapy -
Marc Dror Michaelson, MD, PhD
Clinical Director, Genitourinary Cancer Center
Recent Article
Modified Paclitaxel Plus Daily Radiation Helps Noncystectomy Candidates -
Matthew F. Wszolek, MD
Chair of Quality and Safety, Department of Urology, Massachusetts General Hospital, Urological Oncologist, Mass General Cancer Center, Instructor in Surgery, Harvard Medical School
Recent Article
Advancing Trimodality Therapy for Bladder Cancer
-
Michael L. Blute, MD
Chief, Department of Urology, Walter S. Kerr, Jr., Professor of Surgery, Harvard Medical School
Recent Article
Orthotopic Neobladder Reconstruction Restores Quality of Life for Female Cystectomy Patients
-
William Shipley, MD
Andres Soriano Distinguished Professor of Radiation Oncology, Harvard Medical School
Recent Article
Alternative Chemoradiation Regimen of Trimodal Therapy Found Effective for Muscle-invasive Bladder Cancer
Urology Care at Mass General
The Department of Urology at Massachusetts General Hospital offers sophisticated, compassionate care and the most innovative treatments for patients with any type of urological condition.Resource Links
